Perspective · 29 Jun 2023
Conference abstractPublished 5 Sep 2016
Different targeting possibilities using nanoparticles
Fraunhofer Institute for Biomedical Engineering, Germany
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Since many centuries there have been huge challanges in medicine. For example, evolution gave birth to an extremely useful structure: The blood-brain barrier (BBB) that protects our central nervous system homeostasis by shielding off toxic substances and pathogens. But biologically valuable does not always mean pharmacologically welcome. The BBB does not distinguish between friend and foe and causes many potentially effective brain therapeutics to fail in vivo - not because of a lack of potency, but because they cannot pass this barrier. This dilemma especially comes into focus for the rapidly growing numbers of neurodegenerative disorders. Another example comes from tumor therapy. The main disadvantages of conventional chemotherapy are modest tumor response and dose limiting side effects because of non-specific action of drugs to all fast proliferating tissues. Both described scenarios are still unsolved problems in modern medicine. However today, we can use the elegant approach of molecular Trojan Horses: the fast-emerging field of nanotechnology offers the possibility to enlarge the pool of substances by packing promising drugs into nanoparticles (NP). NP show a high drug loading efficiency with minor drug leakage as well as the ability to circumvent multiÃ?¬drug resistance paired with good storage stability. By this, we can mask the original physicochemical properties of substances and even surface-modify the NP with ligands targeting specific receptors e.g. at the BBB or on cancer cells. The advantages are tempting: Apart from reducing peripheral doses and consequently side effects, drugs can be delivered directly to target structures.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2022
Prondicic acid (2-oxetanon-3, 4-diacetic acid): discovery, in silico drug design, syhtehic route, and importance as a highly potent enzyme inhibitor and the possible uses as a funtional group attached to dihalogenated anti-cancer drug compounds to increase efficacy and enzymatic target binding for more specific tumour targeting
Research article · 2018
Air Pollutants and their Possible Health Effects at Different Locations in Dhaka City
Short communication · 30 Dec 2024
Nanomedicine in Cancer Treatment: Designing Nanoparticles for Targeted Delivery
Conference abstract · 5 Dec 2016
Magnetic Fe3O4-based nanoparticles as drug delivery systems for targeted cancer therapy
More from this journal
The newest in Medicinal Chemistry.
Brief report · 30 Jun 2026
Covalent Drugs in Medicinal Chemistry: Emerging Opportunities and Ongoing Challenges
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Sylvia Wagner”

